VanEck Global Global Healthcare Leaders ETF HLTH
Fund description: HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. HLTH aims to provide investment returns before fees and other costs which track the performance of the Index.
Index description: The MarketGrader Developed Markets (ex-Australia) Health Care Index consists of 50 fundamentally sound companies with the best growth at a reasonable price (GARP) attributes in the healthcare sector from developed markets excluding Australia.
Management style: Replication
Country of domicile: Australia
as at 25-May-22
-
Exchange
ASX -
ASX code
HLTH -
Bloomberg index code
MGHCAUNR -
Index provider
MarketGrader -
NAV1
$10.10 -
Units outstanding1
8,000,381 -
Net assets1
$80.8M -
Number of holdings1
50 -
Inception date2
08-Sep-20 -
ASX commencement
10-Sep-20
2The date the ETF was seeded prior to quotation on ASX.
as at 25-May-22
-
Dividend frequency
1 each year -
Management costs p.a.
0.45% - Investment management team »
- Market Announcements
- HLTH Fact Sheet
- HLTH Fund Flyer
*The NAV is generally calculated daily after all markets are closed for that day based on the closing price of the securities on the relevant foreign stock exchange. The NAV is then converted to AUD based on the relevant London WM Reuters 4pm exchange rate. This means, due to Australia’s time zone, that the NAV will generally not be updated until around 1pm next business day.
Key benefits
Global growth opportunity
A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services
A portfolio of global healthcare leaders comprising the most fundamentally strong companies
Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector
Targeted exposure and diversification
A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies
Trading information
-
ASX code
HLTH -
IRESS code
HLTH.AXW -
Units outstanding
8,000,381 -
ISIN
AU0000102683
Fees and other costs
-
Management costs p.a.
0.45%
Key risks
An investment in the ETF carries risks associated with: ASX trading time differences, financial markets generally, individual company management, industry sectors, foreign currency, currency hedging, country or sector concentration, political, regulatory and tax risks, fund operations, liquidity and tracking an index. See the PDS for details.
Prices as at 25-May-22
Performance history (%) View all ETFs » View all indices »
1 Mth | 3 Mths | 6 Mths | 1 Yr | 3 Yrs p.a. | 5 Yrs p.a. | 10 Yrs p.a. | ETF Inception p.a. | |
---|---|---|---|---|---|---|---|---|
Price return | -4.92 | -8.16 | -12.57 | -1.84 | -- | -- | -- | 1.90 |
Income return | 0.00 | 0.00 | 0.00 | 0.35 | -- | -- | -- | 0.22 |
Total return | -4.92 | -8.16 | -12.57 | -1.49 | -- | -- | -- | 2.12 |
Index (MGHCAUNR) | -4.91 | -8.06 | -12.39 | -1.06 | 11.94 | 14.00 | 20.30 | 2.59 |
1 Mth | 3 Mths | 6 Mths | 1 Yr | 3 Yrs p.a. | 5 Yrs p.a. | 10 Yrs p.a. | ETF Inception p.a. | ||
---|---|---|---|---|---|---|---|---|---|
Price return | -0.01 | -12.77 | -10.86 | 5.99 | -- | -- | -- | 5.36 | |
Income return | 0.00 | 0.00 | 0.00 | 0.38 | -- | -- | -- | 0.24 | |
Total return | -0.01 | -12.77 | -10.86 | 6.37 | -- | -- | -- | 5.60 | |
Index (MGHCAUNR) | 0.06 | -12.65 | -10.65 | 6.86 | 13.05 | 16.60 | 20.90 | 6.10 |
Top ten holdings (%) View all daily holdings » as at 30-Apr-22
Holding name |
Ticker
|
No. of securities held | Market value | % of Fund net assets |
|
---|---|---|---|---|---|
NOVARTIS AG |
NOVN SW
|
19,873 | 2,492,362 | 2.89 | |
SONOVA HOLDING AG |
SOON SW
|
4,521 | 2,328,032 | 2.70 | |
VERTEX PHARMACEUTICALS INC |
VRTX US
|
5,331 | 2,049,582 | 2.38 | |
MERCK & CO INC |
MRK US
|
16,285 | 2,032,388 | 2.36 | |
HALOZYME THERAPEUTICS INC |
HALO US
|
35,273 | 1,980,430 | 2.30 | |
NOVO NORDISK A/S |
NOVOB DC
|
12,054 | 1,953,991 | 2.27 | |
BRISTOL-MYERS SQUIBB CO |
BMY US
|
18,180 | 1,925,573 | 2.23 | |
INCYTE CORP |
INCY US
|
18,088 | 1,907,938 | 2.21 | |
REGENERON PHARMACEUTICALS INC |
REGN US
|
2,056 | 1,906,888 | 2.21 | |
JOHNSON & JOHNSON |
JNJ US
|
7,457 | 1,893,604 | 2.20 | |
Top ten total (%) | 23.75 |
Country weightings (%) as at 30-Apr-22
-
Country
Weightings (%) -
United States
53.6 -
Switzerland
13.8 -
France
5.8 -
Japan
5.4 -
Italy
4.0 -
South Korea
3.8 -
China
3.6 -
Denmark
2.3 -
Belgium
2.2 -
Germany
2.0 -
Luxembourg
1.9 -
New Zealand
1.5 -
Other/Cash
0.1 -
Total
100.0
Sub-sector weightings (%) as at 30-Apr-22
-
Sector
Weightings (%) -
Pharmaceuticals
25.7 -
Biotechnology
25.0 -
Life Sciences Tools & Services
22.4 -
Health Care Equipment & Supplies
20.9 -
Health Care Providers & Services
5.9 -
Other/Cash
0.1 -
Total
100.0